share_log

BIOLASE Announces Delisting From Nasdaq

BIOLASE Announces Delisting From Nasdaq

biolase宣佈從納斯達克退市
Biolase ·  06/18 12:00

LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b). Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on June 20, 2024.

2024年6月18日,BIOLASE公司(NASDAQ:BIOL),一家全球領先的牙科激光公司,今天宣佈,該公司收到了納斯達克的通知,納斯達克已決定將該公司普通股的股票從納斯達克股票市場除牌。這是由於未能滿足納斯達克上市規則5550(a)(2)中的1.00美元最低競價價格上市要求以及未能符合納斯達克的250萬美元最低股東權益的持續上市要求或任何備選要求中的任何一項。該公司普通股在納斯達克交易所的交易暫停將從2024年6月20日交易開始生效。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論